Search Results

You are looking at 1 - 10 of 96 items for :

  • "thalidomide" x
Clear All
Full access

Ashraf Z. Badros

patterns vary considerably because of conflicting data about its effectiveness. Currently, NCCN recommends thalidomide (category 1 recommendation) with or without prednisone (category 2B) for maintenance therapy; the roles of interferon and corticosteroids

Full access

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades and Kenneth C. Anderson

thalidomide analogs in human multiple myeloma cells: therapeutic implications . Blood 2002 ; 99 : 4525 – 4530 . 16. Jagannath S Barlogie B Berenson J . A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma . Br J Haematol

Full access

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial . Lancet 2007 ; 307 : 1209 – 1218

Full access

Jean-Luc Harousseau and Philippe Moreau

. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies . Blood 2006 ; 107 : 2633 – 2638 . 18. Moreau P Hullin C Garban F . Tandem autologous

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

Oncology Study Group (IOSG) phase II protocol . Am J Hematol 2000 ; 63 : 125 – 130 . 26 D’Amato RJ Loughman MS Flynn E Folkman J . Thalidomide is an inhibitor of angiogenesis . Proc Natl Acad Sci U S A 1994 ; 91 : 4082 – 4085 . 27

Full access

Ashraf Badros

information in MM, which has led to re-evaluation of the definition of high-risk disease. 3 , 4 The use of nonchemotherapeutic antimyeloma agents is also driving efforts for improved prognostication. Recent data suggest that agents such as thalidomide

Full access

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades and Kenneth Anderson

manifestations of treatment-related PN can be life-threatening but this is, fortunately, very rare. 7 , 9 , 12 Thalidomide-Induced PN (TiPN) Thalidomide has been shown to produce a small- and large-fiber sensory PN with distal symmetric loss of all

Full access

Philip L. McCarthy

increased. 1 This improved OS is likely from the use of novel agents that improve PFS, including the immunomodulatory drugs (IMiDs) thalidomide 2 , 3 and lenalidomide, 4 - 7 and the proteasome inhibitor bortezomib. 8 - 13 These drugs, usually as part of

Full access

Ruben Niesvizky and Ashraf Z. Badros

Therapies such as thalidomide, bortezomib, and lenalidomide have provided meaningful benefits in multiple myeloma (MM), such as improved response rates and improved duration of response, but they have been associated with an increased risk of

Full access

Jason Gotlib and Peter L. Greenberg

Research funds for the authors were received from Amgen, Celgene, Johnson & Johnson, and Novartis. References 1 Dredge K Marriott JB Dalgleish AG . Immunological effects of thalidomide and its chemical and functional analogs